NCT06706427 - Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

September 26, 2029

Conditions

Bietti Crystalline Corneoretinal Dystrophy

Interventions

BIOLOGICAL

NGGT001

Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.

Trial Locations (2)

361000

Xiamen Eye Center of Xiamen University, Xiamen

400000

Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing

All Listed Sponsors

lead

NGGT (Suzhou) Biotechnology Co., Ltd.

INDUSTRY